K Patel

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
  2. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
  3. pmc Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection
    Ian R White
    Department of Disease and Biomarker Proteomics, GlaxoSmithKline Pharmaceuticals, Stevenage, UK
    J Transl Med 5:33. 2007
  4. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
  5. ncbi request reprint The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:535-41. 2005
  6. doi request reprint Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Gastroenterol Hepatol 6:242-7. 2008
  7. doi request reprint High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    Hepatology 53:1809-18. 2011
  8. doi request reprint An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C
    K Patel
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
    J Viral Hepat 16:178-86. 2009
  9. doi request reprint Noninvasive tools to assess liver disease
    Keyur Patel
    Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Gastroenterol 26:227-33. 2010
  10. doi request reprint Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Unit and DUMC, Durham, NC, USA
    Antivir Ther 16:1341-6. 2011

Detail Information

Publications51

  1. doi request reprint Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  2. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
    ..Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment...
  3. pmc Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection
    Ian R White
    Department of Disease and Biomarker Proteomics, GlaxoSmithKline Pharmaceuticals, Stevenage, UK
    J Transl Med 5:33. 2007
    ..To identify potential biomarkers of fibrosis, we compared serum protein expression profiles in patients with chronic hepatitis C (CHC) virus infection and fibrosis...
  4. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
    ..We examined factors that influence the participation of gastroenterologists and hepatologists in clinical research...
  5. ncbi request reprint The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 10:535-41. 2005
    ..We compared the Catrimox-14 WB assay with a standard serum assay...
  6. doi request reprint Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Gastroenterol Hepatol 6:242-7. 2008
    ..We hypothesized that a noninvasive test of liver fibrosis can accurately stage liver fibrosis. We prospectively evaluated the FIBROSpect II (FSII) biomarker panel versus pathology assessment and a quantitative measure of fibrosis...
  7. doi request reprint High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    Hepatology 53:1809-18. 2011
    ..A model averaging approach for identified peptides resulted in an AUROC of 0.86 in the validation cohort, and correctly identified virologic response in 71% of patients without the favorable IL28B "responder" genotype...
  8. doi request reprint An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C
    K Patel
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
    J Viral Hepat 16:178-86. 2009
    ..Lower index scores at baseline that continue to decline likely reflect reduced fibrogenesis activity in patients with successful antiviral responses to therapy...
  9. doi request reprint Noninvasive tools to assess liver disease
    Keyur Patel
    Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Gastroenterol 26:227-33. 2010
    ..This review highlights some of the recent advances and potential application of these tools in clinical practice...
  10. doi request reprint Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Unit and DUMC, Durham, NC, USA
    Antivir Ther 16:1341-6. 2011
    ..Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients...
  11. doi request reprint Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients
    Keyur Patel
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Gastroenterol Hepatol 26:1182-8. 2011
    ..We retrospectively investigated the relationship between host metabolic variables, including IR and hepatic steatosis, to hepatic fibrosis in Asian-region CHC genotype 2/3 patients...
  12. pmc FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus
    Keyur Patel
    Department of Gastroenterology and Hepatology, Duke Clinical Research Institute, Durham, NC 27715, United States
    World J Gastroenterol 17:4581-9. 2011
    ..To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort...
  13. doi request reprint Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  14. pmc Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
    P J Clark
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    J Viral Hepat 19:332-40. 2012
    ..LDL-C remains significantly associated with SVR for heterozygous IL28B genotype patients, where LDL-C and HCV RNA burden may identify those patients with high or low likelihood of cure with pegIFN/RBV therapy...
  15. doi request reprint Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis
    A B Jazwinski
    Division of Gastroenterology and Hepatology, Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    J Viral Hepat 19:278-82. 2012
    ..Although apoptosis may still contribute to hepatitis C virus (HCV)-mediated steatosis, our results suggest that serum CK-18 will not be a clinically useful test for identifying significant steatosis in CHC...
  16. ncbi request reprint Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C
    J G McHutchison
    Division of Gastroenterology, Gastrointestinal Hepatology Research Program, Duke Clinical Research Institute, Durham, NC 27715, USA
    Aliment Pharmacol Ther 27:422-32. 2008
    ..Treatment options are limited for patients with hepatitis C virus who do not experience sustained viral eradication with pegylated interferon and ribavirin therapy...
  17. doi request reprint Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase
    C L Ward
    Department of Virology, GlaxoSmithKline, Stevenage, Hertfordshire, UK
    J Viral Hepat 15:571-7. 2008
    ..Ribavirin, a weak inhibitor of HCV replication, does not select for resistance mutations in the sequence of the HCV RNA polymerase...
  18. doi request reprint Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C
    K Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    J Viral Hepat 18:331-7. 2011
    ..099). Short-term Rosuvastatin monotherapy is not associated with significant changes in serum or lipid fraction HCV RNA in NR patients. HCV co-localizes with the lowest density lipid fractions in serum...
  19. ncbi request reprint Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo
    Rebecca Lim
    School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia
    Hepatology 43:1074-83. 2006
    ..05). In conclusion, interferon alpha-based treatment reduced the number of hepatic progenitor cells in chronic liver injury by modulating apoptosis, proliferation, and differentiation. Supplementay material for this article can..
  20. ncbi request reprint Relationship of smoking and fibrosis in patients with chronic hepatitis C
    Anouk Dev
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Gastroenterol Hepatol 4:797-801. 2006
    ..These cytokine levels are increased in animals with cirrhosis and in human beings with CHC. We studied whether the concentrations of VEGF, VEGF-D, s-Flt, and s-KDR were increased in CHC smokers with and without hepatic fibrosis...
  21. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  22. ncbi request reprint Treatment of acute hepatitis C infection: more pieces of the puzzle?
    Amany Zekry
    J Hepatol 42:293-6. 2005
  23. pmc Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation
    Ravi Jhaveri
    Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 197:283-91. 2008
    ..We hypothesize that specific sequence polymorphisms in HCV genotype 3 core protein may be associated with hepatic intracellular lipid accumulation...
  24. doi request reprint Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Edmonton, Canada
    Clin Gastroenterol Hepatol 6:701-6. 2008
    ..A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-naïve patients with genotype 2/3, chronic hepatitis C virus infection...
  25. ncbi request reprint Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients
    Keyur Patel
    Hepatology 37:1222; author reply 1222-3. 2003
  26. ncbi request reprint Kinetics of hepatitis C virus reinfection after liver transplantation
    Kimberly A Powers
    Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
    Liver Transpl 12:207-16. 2006
    ..In conclusion, we have quantified liver reinfection dynamics in the absence of posttransplantation antiviral therapy. Our findings support the notion that early antiviral therapy may delay or prevent reinfection...
  27. ncbi request reprint HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 43:241-9. 2006
    ..HLA zygosity at 1, 2, or 3 alleles was not associated with fibrosis stage, liver inflammation, or treatment outcome. In conclusion, HLA class I allelic diversity has a minor influence on FPRs and disease severity in CHC...
  28. ncbi request reprint The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  29. ncbi request reprint Risks of a range of alcohol intake on hepatitis C-related fibrosis
    Alexander Monto
    Department of Gastroenterology, University of California at San Francisco, 4150 Clement Street 111B, San Francisco, CA 94121, USA
    Hepatology 39:826-34. 2004
    ..Age, serum ALT, and inflammation are independently associated with fibrosis in multivariate analysis, highlighting the fact that variables other than alcohol intake predominate in the production of hepatic fibrosis...
  30. ncbi request reprint New therapies for chronic hepatitis C virus infection
    Anouk Dev
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Curr Gastroenterol Rep 6:77-86. 2004
    ....
  31. ncbi request reprint Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients
    Keyur Patel
    Duke Clinical Research Institute, Division of Gastroenterology, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Postgrad Med 114:48-52, 57-9, 62. 2003
    ....
  32. ncbi request reprint Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
    Keyur Patel
    Hepatology 38:21-4. 2003
  33. ncbi request reprint Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Gastroenterol Hepatol 18:253-7. 2003
    ..However, its use in monitoring fibrosis over time has not been established. The aim of the present study was to assess the serial relationships between HA and liver fibrosis before and after treatment...
  34. ncbi request reprint Future therapy of hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Hepatology 36:S245-52. 2002
    ..Most of these newer therapies are unlikely to be available for routine clinical use in the next 3 to 5 years...
  35. ncbi request reprint Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Gastroenterology 123:1061-9. 2002
    ..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
  36. ncbi request reprint Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
    Magali Bouvier-Alias
    Department of Virology EA 3489, Hopital Henri Mondor, Universite Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
    Hepatology 36:211-8. 2002
    ..Nevertheless, the total HCV core Ag assay cannot be used as a marker of viral replication for HCV RNA values below 20,000 IU/mL, limiting its use in the monitoring of late events during and after antiviral treatment...
  37. ncbi request reprint Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection
    Stephen Pianko
    Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA
    J Interferon Cytokine Res 22:483-9. 2002
    ..IFN monotherapy nonresponder patients tended to have a higher HIC. With IFN plus ribavirin, the sustained virologic response rate was not affected by the HIC...
  38. ncbi request reprint Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  39. ncbi request reprint Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    J Hepatol 41:935-42. 2004
    ....
  40. ncbi request reprint Hepatitis C and steatosis
    Anouk Dev
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Centre, P O Box 17969, Durham, NC 27715, USA
    Clin Liver Dis 8:881-92, ix. 2004
    ..Research efforts should continue to focus on defining the complex viral and host interactions involved in the pathogenesis of HCV-related steatosis so that future therapeutic strategies may be accurately and appropriately targeted...
  41. ncbi request reprint Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Cleve Clin J Med 71:S8-12. 2004
    ..Early virologic response is a good predictor of eventual sustained response for patients with HCV genotype 1 infection. Despite important gains in treating chronic hepatitis C, many treatment challenges remain...
  42. ncbi request reprint The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice
    John G McHutchison
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Centre, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27707, USA
    J Hepatol 44:411-21. 2006
  43. ncbi request reprint A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients
    John G McHutchison
    The Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    J Hepatol 44:88-96. 2006
    ..This Phase I, open-label, dose-escalation trial of ISIS 14803 was performed in chronic HCV patients...
  44. ncbi request reprint Steatosis and chronic hepatitis C virus infection: mechanisms and significance
    Keyur Patel
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, P O Box 17969, Durham, NC 27715, USA
    Clin Liver Dis 9:399-410, vi. 2005
    ..This may provide novel future therapeutic strategies that may help modulate disease progression in relation to steatosis in HCV infection...
  45. ncbi request reprint Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin
    Stephen J Rulyak
    Department of Medicine, Division of Gastroenterology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Am J Gastroenterol 100:332-7. 2005
    ..The aims of this study were to determine the effect of pretreatment hepatic iron concentration (HIC) on response to combination therapy with interferon and ribavirin, and to examine the change in HIC associated with this treatment...
  46. ncbi request reprint Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection
    Steven L Condron
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Transplantation 80:145-8. 2005
    ..Recent studies from selected centers have suggested that older donor age is associated with worse outcomes after transplantation for HCV...
  47. doi request reprint GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality
    Hans L Tillmann
    Gastroenterology 134:2191; author reply 2191-2. 2008
  48. ncbi request reprint Tinkering and tailoring with HCV therapy: can we get away with less?
    Amany Zekry
    Hepatology 40:1249-51. 2004
  49. ncbi request reprint Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions
    Anouk Dev
    Am J Gastroenterol 98:2344-7. 2003
  50. doi request reprint Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia
    Karen R Canlas
    Division of Gastroenterology and Hepatology, Duke University Medical Center, Durham, NC 27705, USA
    J Clin Gastroenterol 42:844-8. 2008
    ..We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia...
  51. ncbi request reprint Population-based hepatitis C surveillance and treatment in a national managed care organization
    Deborah Shatin
    UnitedHealth Group, Center for Health Care Policy and Evaluation, 12125 Technology Drive, MN002 0260, Minneapolis, MN 55344, USA
    Am J Manag Care 10:250-6. 2004
    ..To use a national population-based automated claims database to study the testing rate, prevalence, and prescribing patterns for chronic hepatitis C...